Generalized Modules for Membrane Antigens (GMMA), an outer membrane vesicle‐based vaccine platform, for efficient viral antigen delivery. Issue 11 (14th November 2022)

• Record Type: Journal Article
• Authors: Hu, Kai; Palmieri, Elena; Samnuan, Karnyart; Ricchetti, Beatrice; Oldrini, Davide; McKay, Paul F.; Wu, Guanghui; Thorne, Leigh; Fooks, Anthony R.; McElhinney, Lorraine M.; Goharriz, Hooman; Golding, Megan; Shattock, Robin J.; Micoli, Francesca
• Is Part Of: Journal of extracellular vesicles. Volume 11:Issue 11(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-11-14
• Subjects: immune response -- influenza -- outer membrane vesicle -- rabies -- vaccine platform; Cells -- Mechanical properties -- Periodicals; Transport Vesicles; Cells -- Mechanical properties; Periodicals; Fulltext; Internet Resources; Periodicals; Electronic journals; Periodicals; 571.63
• DOI: 10.1002/jev2.12247
• Languages: English
• ISSNs: 2001-3078

Abstract

Abstract: Vaccine platforms enable fast development, testing, and manufacture of more affordable vaccines. Here, we evaluated Generalized Modules for Membrane Antigens (GMMA), outer membrane vesicles (OMVs) generated by genetically modified Gram‐negative bacteria, as a vaccine platform for viral pathogens. Influenza A virus hemagglutinin (HA), either physically mixed with GMMA (HA+STmGMMA mix), or covalently linked to GMMA surface (HA‐STmGMMA conjugate), significantly increased antigen‐specific humoral and cellular responses, with HA‐STmGMMA conjugate inducing further enhancement than HA+STmGMMA mix. HA‐STmGMMA conjugate protected mice from lethal challenge. The versatility for this platform was confirmed by conjugation of rabies glycoprotein (RABVG) onto GMMA through the same method. RABVG+STmGMMA mix and RABVG‐STmGMMA conjugate exhibited similar humoral and cellular response patterns and protection efficacy as the HA formulations, indicating relatively consistent responses for different vaccines based on the GMMA platform. Comparing to soluble protein, GMMA was more efficiently taken up in vivo and exhibited a B‐cell preferential uptake in the draining lymph nodes (LNs). Together, GMMA enhances immunity against viral antigens, and the platform works well with different antigens while retaining similar immunomodulatory patterns. The findings of our study imply the great potential of GMMA‐based vaccine platform also against viral infectious diseases.